😀 Great ANR-2025 results for the CEPR!! 👏 Congratulations to Christophe Paget and Nathalie Heuzé-Vourc’h for their participation in the ALS-IMMUNE (CE17) and PETREL (CE18) programs! 👏 Congratulations to Noémie Alphonse and Benoît Briard for obtaining their Young Researcher grants (ANR JCJC, CE15), Ti-LAB and AspSTAT5 respectively. This bodes well for exciting discoveries and a new dynamic for our teams!
The PEPR 2024 project is coordinated by Mathieu Epardaud (ISP – INRAe/University of Tours) and Thomas Sécher (CEPR – Team 3 – Inserm/University of Tours). 🔬- InHEALation – aims to develop an innovative prophylactic and therapeutic inhaled platform against respiratory viruses.
Thomas obtained a one-year grant from LCC37 to support his study
Noemie Alphonse obtained EMBO and MSCA (Marie Skłodowska-Curie Actions) Postdoctoral Fellowships.
The emergence of pandemic respiratory viruses is a major concern. Those viruses include coronaviruses such as SARS-CoV-2 and influenza A viruses (IAV). There are currently no efficient drugs against coronaviruses and the efficacy of anti-IAV drugs is disputed. Vaccination should constitute the most preventive strategy. However, the intrinsic antigenic drift of IAV impairs vaccine protection. Besides, previous coronaviruses crises showed that poorly neutralizing antibodies developed after vaccination may enhance subsequent infection. Current vaccine hesitancy also remains a barrier to full population inoculation against SARS-CoV-2. Our ANR project is thus aimed to develop an innovative metabolic therapy against those two viruses, delivered via the pulmonary route, based on (i) recent evidence that metabolites are key effectors of the host antimicrobial response and (ii) our preliminary data which identified two metabolites with anti-IAV and anti-SARS-CoV-2 antiviral activity. source : https://anr.fr/Projet-ANR-21-CE18-0061